News
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
2don MSN
Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity
American Eagle says Sydney Sweeney ad 'is and always was about the jeans' Tom Brady responds to Scottie Scheffler's comments ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
1d
GlobalData on MSNEli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.
AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...
Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post ...
We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim ...
Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results